FN2 Earnings Intelligence

Regeneron Pharmaceuticals, Inc. analyst ratings

Regeneron Pharmaceuticals, Inc. (REGN) analyst consensus, price targets, and firm-level rating history from FN2 Research.

Analyst Consensus ?

ConsensusBuy49 ratings
Bullish3469.4%
Neutral1530.6%
Bearish00.0%

Analyst 52W Price Targets

$695.16Current
$584Low
$851.6Average
$1,292High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Guggenheim Buy BuyMaintainJul 21, 2026
Piper Sandler Overweight OverweightMaintainJul 9, 2026
Morgan Stanley Equal Weight Equal WeightMaintainJul 8, 2026
Truist Securities Buy BuyMaintainJul 7, 2026
RBC Capital Sector Perform Sector PerformMaintainJul 7, 2026
Benchmark Buy HoldUpgradeJul 7, 2026
HSBC Buy BuyMaintainJul 6, 2026
Cantor Fitzgerald Overweight OverweightMaintainJul 6, 2026
Show 41 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $695.16. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
GuggenheimYatin Suneja$1,000$675.72 +43.9%Jul 21, 2026
Piper SandlerBiren Amin$854$662.88 +22.8%Jul 9, 2026
Morgan StanleyTerence Flynn$730$676.23 +5.0%Jul 8, 2026
Truist FinancialAnalyst unavailable$769$670.54 +10.6%Jul 7, 2026
HSBCAnalyst unavailable$800$643 +15.1%Jul 6, 2026
Cantor FitzgeraldAnalyst unavailable$750$654.27 +7.9%Jul 6, 2026
Canaccord GenuityJohn Newman$875$629.68 +25.9%May 19, 2026
Wolfe ResearchAlexandria Hammond$860$629.36 +23.7%May 18, 2026
Evercore ISIAnalyst unavailable$825$619.84 +18.7%May 18, 2026
RBC CapitalAnalyst unavailable$707$619.62 +1.7%May 18, 2026
See 125 more

Track every rating change on REGN the moment it posts. Free to start.

Start free